They are not "academics" as in "professors", after all, they don't have classes to teach, but they are researchers and researchers like to talk about their research projects. There's no great harm in that, but it isn't getting Flucide any closer to approval.
If they HAD published 6 papers by now the stock would be well above $0.625 IMHO. Validity of claims is key with big biotech investors, and published results are the gold standard.
News 
Market Data 
Discover 
